Efficacy and safety of albendazole alone versus albendazole in combination with ivermectin for the treatment of Trichuris trichiura infections: An open-label, randomized controlled superiority trial in south-western Uganda

Marta Sólveig Palmeirim,Eveline Hürlimann,Prudence Beinamaryo,Hilda Kyarisiima,Betty Nabatte,Jan Hattendorf,Peter Steinmann,Jennifer Keiser

DOI: https://doi.org/10.1371/journal.pntd.0012687

2024-11-28

PLoS Neglected Tropical Diseases

Abstract:Trichuris trichiura , a soil-transmitted helminth (STH), often persists after a single dose of anthelminthic treatment. To overcome limited efficacy against T . trichiura of benzimidazoles (albendazole or mebendazole), the primary drugs used in mass drug administration (MDA) campaigns, the World Health Organization endorses the use of a combination of ivermectin and albendazole as a more effective treatment to be used for preventive chemotherapy. Given observed considerable differences in efficacy of the combination therapy over albendazole monotherapy, between different settings, it is necessary to evaluate the performance of the combination before introducing it on a larger scale. This open-label, randomized controlled superiority trial in two Ugandan primary schools enrolled eligible 6- to 12-year-olds positive for T . trichiura . Participants were randomized 1:1 to receive either a single dose of albendazole alone or co-administered albendazole and ivermectin. Adverse events were monitored at three and 24h post-treatment. Follow-up samples were collected 14 to 21 days post-treatment for efficacy assessment. The combination of albendazole with ivermectin showed superior efficacy against T . trichiura compared to albendazole alone, both in terms of cure rates (31.3% versus 12.3%, difference 18.9%-points, 95% CI 6.2–31.2, p < 0.004) and in terms of egg reduction rates (ERRs; 91.4% versus 52.7%). A higher cure rate against co-infecting Ascaris lumbricoides was observed in the combination compared to the albendazole monotherapy arm (100% versus 83.9%). Both therapies showed an excellent safety profile with few and only mild and transient treatment emergent adverse events observed in the albendazole monotherapy and albendazole plus ivermectin arm (total of 22 and 19 events, respectively). In conclusion, the efficacy of the combination therapy against T . trichiura in Uganda is superior to that of albendazole alone. Given the high ERRs observed albendazole-ivermectin might aid in eliminating morbidity, an important target of STH control programs. Trial registration (clinicaltrials.gov): NCT06037876. Despite several decades of preventive chemotherapy with single-dose albendazole distribution to at-risk populations, soil-transmitted helminth infections remain of public health concern in Uganda. The Ministry of Health has stated interest in the introduction of potentially more efficacious treatment strategies against T . trichiura such as the use of a combination of the two deworming drugs (ivermectin and albendazole) instead of only albendazole as currently used. Given significant differences in efficacy between the combination therapy compared to albendazole monotherapy against T . trichiura in different settings, we conducted a randomized clinical trial in two Ugandan primary schools to assess whether in Uganda the combination is more efficacious than albendazole alone. The findings of our study confirmed higher efficacy against T . trichiura in the study area. Both treatment regimens were well tolerated. In conclusion, we conceive that the introduction of the combination therapy is advantageous and its introduction into the existing STH control programme should now be evaluated from a recipient and provider perspective.

tropical medicine,parasitology